201247212 六、發明說明： 【發明所屬之技術領域】 本發明係關於一種使用人蔘花萃取物的新用途，尤其 有關一種使用人蔘花萃取物預防或治療因血中尿酸過高所 引起的疾病或徵狀的用途. 【先前技術】 尿酸是人體中普林（Purine)代謝的最終產物，需排出體 外’ 一般來說血液中的尿酸正常值為每1〇〇毫升中含2到 7毫克，如果超過7毫克（飽和值）尿酸就會沉積在血液和組 織中。沉澱在關節引起痛風石，沉積在腎臟引起尿酸結石 及腎功能衰竭，在血管引起高血脂、動脈硬化及高血壓’ 最嚴重是引起心肌梗塞及中風，也會引起糖尿病。 尿酸是由普林代謝所產生，而普林則存在於食物中或 體内的細胞。一般而言，體内尿酸約三分<—來自飲食’ 另約三分之二來自身體的新陳代謝。正常人約有三分之二 的尿酸由腎臟經尿液排出， 謝，另約有小於百分之一法 ，約三分之一由腸内細菌分解代 由汗腺排泄。但腎臟功能異常的 病人則由腎臟排泄的量減少，相對地由腸道排泄的量會增 加。因此’若尿酸產生過多或排泄減少，均會造成血中尿 酸過高。身體若是長時間處在高尿酸的情況下，就會使尿201247212 VI. Description of the invention: [Technical field to which the invention pertains] The present invention relates to a novel use of a human scented flower extract, in particular to a method for preventing or treating diseases caused by excessive uric acid in blood by using a human scented flower extract. Or the use of symptoms. [Prior Art] Uric acid is the final product of Purine metabolism in the human body and needs to be excreted in vitro. Generally, the normal value of uric acid in blood is 2 to 7 mg per 1 ml. If more than 7 mg (saturated value) of uric acid is deposited in the blood and tissues. Precipitation causes tophi in the joints, deposits in the kidneys causing uric acid stones and renal failure, causing hyperlipidemia, arteriosclerosis and hypertension in the blood vessels. The most serious cause is myocardial infarction and stroke, and can also cause diabetes. Uric acid is produced by Purin metabolism, while Purin is present in food or in cells in the body. In general, uric acid in the body is about three points <- from the diet'. About two-thirds of the metabolism comes from the body. About two-thirds of normal people's uric acid is excreted by the kidneys through the urine. Thanks, there are about less than one percent of the method, and about one-third is excreted by the intestinal guts and excreted by the sweat glands. However, in patients with abnormal renal function, the amount of excretion by the kidneys is reduced, and the amount of excretion by the intestines is increased. Therefore, if the uric acid is excessively produced or the excretion is reduced, the blood uric acid is too high. If the body is in a high uric acid for a long time, it will make the urine
201247212 增加的趨勢》根據國家衛生研究院的研究顯示，國内目前 三十歲以上的男性人口中，痛風的盛行率高達百分之三點 三。這與經濟的高度快速成長，民眾飲食習慣改變，即對 動物性蛋白、脂肪及酒的消費量大增有相當大的關係。肥 胖的人口越來越多、越來越年輕化，因此使得尿酸過高的 人口急遽上升，痛風發作的年齡層也越來越年輕。 依據歐美國家對痛風患者死亡原因的統計，因痛風而 產生的併發症中，以合併缺血性心臟病占最多其次是尿 毒症、腦血管疾病等等。而在亞洲地區日本的研究卻是以 尿毒症居首位，其次才是缺血性心臟病、腦血管疾病。不 論何種併發症’都是痛風患者必須多重視的。 目前治療痛風的方式一般而言，在急性痛風期，最重 要的是減輕疼痛的發作，而非降低尿酸濃度。首先給予受 侵犯的關節充分休息，通常會採取給予秋水仙素的治療方 式，但因秋水仙素作用時間緩慢，所以當秋水仙素無法抑 制發炎而持續疼痛時就要利用非類固醇類消炎止痛劑。但 在老人及肝腎功能不好的病人，如要使用秋水仙素，得非 常小心《秋水仙素用於急性期的治療，當關節疼痛改善之 際’常會造成腹>寫等腸胃不適症狀。另外，在降尿酸藥物 方面，主要使用促進尿酸排泄藥物（Benzbr〇marone)及抑制 尿酸生成藥物（Allopurinol)醫師得視病患的病情、合併症等 來決定使用的藥物種類。但這兩種藥物的副作用都會使肝 臟受損，引起GOP及GDP指數上升，所以在治療期間必 須定時檢查肝功能。 201247212 人篆（Radix Gingseng)為五加科人蔘屬植物 c. A.Meyer的乾燥根，已有許多研究顯示，人蔘中 3有人蔘皂苷、人蔘多醣、蛋白質胺基酸等多種化學成 刀，而其中以人蔘皂苷為其主要的要效成分❶目前已知從 人蔘中分離而得到80多種人蔘皂苷，已有研究顯示是人蔘 4普Rbl、Rd、Rgl、Rg3、Rhl及Rh2具有制腫瘤細胞增 殖與浸潤、轉移，抑制血管内皮細胞增生，促進癌凋亡， 調節免疫功能，調整血糖、延緩衰老及抗疲勞等作用。而 人蔘化在近年來的研究也顯示含有大量皂苷活性物質礦 物質微量元素及生物鹼，其中花蕾皂苷含量比人蔘根高5 倍以上。具有益氣活血、調節内分泌、促進新陳代謝等功 效又能清熱消炎、平肝火 '降血壓等多種保健功效，因此 廣泛被當作食用茶作為養生保健之用。也有研究顯示人蔘 花萃取物在小鼠實驗上具有抗疲勞之作用。 【發明内容】 本發明的一主要目的在提供一種預防或治療因血中尿 酸過尚所引起的疾病或徵狀的有效成份。 本發明的另一目的在提供一種預防或治療因血中尿酸 過高所引起的疾病或徵狀的藥物或醫藥組合物。 本發明的又一目的在提供一種預防或治療因血中尿酸 過高所引起的疾病或徵狀的中草藥萃取物。 為了達成上述發明目的，本發明提供了 一種使用人寨 花萃取物作為有效成分在製備用於預防或治療哺乳類動物 201247212 因血中尿酸過高所引起的疾病或徵狀之藥物的用途其中 該人篸花萃取物係人蔘（Panax ginseng c A Meyer)的礼的 萃取物。 較佳的，該人蔘花萃取物係水萃取物、有機溶劑萃取 物、或二氧化碳超臨界流體萃取物❶更佳的，該有機溶劑 萃取物係C1-C4醇、丙酮、醋酸乙酯或乙醚萃取物。 較佳的，該人蔘花萃取物係一極性溶劑萃取物。更佳 的，該極性溶劑萃取物係水、^―以醇、或它們的混合溶劑 的萃取物。最佳的，該極性溶劑萃取物係水與C1C4醇的混 合溶劑的萃取物，例如該^-以醇係曱醇或乙醇。於本發明 的一較佳具體實施例中，該C1_C4醇萃取物係曱醇。 較佳的，該人蔘花萃取物係以包含下列步驟的方法製 備.於振盪下混合人蔘花粉末與水及甲醇的一混合溶劑； 固液分離該粉末與溶劑的混合物而得到一上清液；及濃縮 該上清液而得到該人蔘花萃取物。 較佳的’該藥物為口服劑型。 較佳的，該因血中尿酸過高所引起的疾病或徵狀為痛 風、高尿酸血症、腎結石或痛風性腎病變。 較佳的，該因血中尿酸過高所引起的疾病或徵狀為痛 風0 較佳的，該因血中尿酸過高所引起的疾病或徵狀為高 尿酸血症β 較佳的’該哺乳類動物為人類。 於下列說明書内容中，本發明證明了人蔘花萃取物的先 6 201247212 行攝取具有增加由尿液排出尿酸的量及降低血液中尿酸的 濃度的功能，並且其藥效優於價格昂貴的人蔘萃取物。 【實施方式】 本發明將以實驗探討人蔘及人蔘花萃取物是否可促進 高尿酸老鼠體内過多之尿酸的排除。人蔘粉末水溶液及人 蔘花萃取物以口服方式先給予大鼠後，再以〇x〇nate (藥名） 誘導大鼠形成高尿酸之模式，觀察人蔘粉末水溶液及人萎 花萃取物是否具有促進誘導高尿酸後之大鼠將體内多餘尿 酸排除之作用。 下面結合實施例對本發明做進一步詳細的描述，但不 以此限制本發明。 實施例一 精科混合均勻之人蔘gzwewg C.A. Meyer)花粉 末樣品10克’加入100 mL的5 0%甲醇水溶液混勻，置於 超音波振盪器上萃取1個小時後，再以1 3000 rpm轉速雖 心10分鐘’取上清液約99 mL置於樣品瓶，減壓乾燥共得 4_18克重，萃取率約41.8% 藥物：Oxonate、纖維素羧曱基醚的鈉鹽 (Carboxy me thy 1 Cellulose Sodium，簡稱 CMC)及尿酸標準 品購自Sigma ;人蔘粉末賭自炳翰製藥；人蔘花萃取物為 本實施例製備者❶ 動物：6-8周大SD公鼠購自樂斯科生物科技公司。2 201247212 隻大鼠飼養-籠，提供大鼠飼料、墊料及充分供應乾淨的 飲水。飼養環境為光照12小時、室溫i 8_28〇c、相對渔度 40-70%環境中。 實驗方法： 實驗前準備：前一天先將老鼠禁食（下午6點至隔天早 上9點）’藥物配置、代謝籠放置及體重測量完畢後，以抽 籤方式分組，每組4-6隻。 樂物配置.0.8% CMC均勻溶於無菌水中，以〇 80/。CMC 水溶液配置40 mg/ml的〇xonate懸浮液，〇x〇nate給予劑 量為200 mg/kg (5 ml/kg)。人蔘粉末以無菌水配置25及50 mg/kg濃度的均勻懸浮液。人蔘花萃取物以無菌水配置1〇 及25 mg/kg濃度的均勻懸浮液。人蔘粉末的劑量為25〇及 500 mg/kg (10 ml/kg);人蔘花萃取物的劑量為1〇〇、250 mg/kg (1 0ml/kg) ° 實驗及採樣：大鼠口服人蔘粉末或人蔘花萃取物3〇分 鐘後再以IP注射誘導藥物Oxonate，並將大鼠置於代謝龍 中3個小時’之後收集其尿液並記錄體積採集血液靜置 30分鐘後以3000 rpm之轉速於4。〇離心15-20分鐘並收集 上層血清。尿液及血清分別分裝後儲存於_2〇度冰箱中備 用。 樣品分析·利用HPLC分析血清及尿液中尿酸含量， 設備及方法如下：B403 HPLC system (TSP P1000 pump、 SN4000 controller、UV6000 UV detector)，使用管柱為 HC C18 Aglient 4.6x250 mm;標準品以 0.02% NaN3 備製為 100 201247212 mg/mL，再稀釋為 0.5、5、6、7、8、10、20、30 pg/mL。 樣品利用0.02% NaN3稀釋至適當之濃度後進行分析。 表一及表二分別列出人蔘粉末及人蔘花萃取物對誘導 產生高尿酸大鼠之影響，其中並列出正常鼠缸（未以藥物 Oxonate誘導）及疾病模型組（以藥物〇xonate誘導且未預先 施予藥物）。. 如表一所示，正常鼠之組別在3小時後尿液中所檢測 出的尿酸排除率平均為398.5 pg/3hr，血清中尿酸含量平均 為1 0.8 8 pg/m卜整體尿酸清除為每分鐘1〇7 ml;而疾病模 型組其尿酸排除率高出正常鼠約有5_6倍之多，整體尿酸 清除為每分鐘也高出6倍，明顯增加，而血清中尿酸濃度 與正常鼠袓比約上升20%。餵食人蔘粉末後緯果顯示，與 疾病模型組相比，觀察到尿液中尿酸排除率及整體尿酸清 除些微增加，而血清尿酸含量與疾病模型組相比並無下降 的趨勢’且服高劑量人蔘粉末之組別亦無降低血清中尿酸 之效果。 如表二所示’正常鼠之組別在3小時後尿液中所檢測 出的尿酸排除率平均為354 3 gg/3h，血清中尿酸含量平均 為10.3 pg/ml ’整體尿酸清除為每分鐘〇 8 ml ;而疾病模型 組其尿酸排除率高出正常鼠-約有6_7倍之多，整體尿酸清 除為每分鐘也高出約5·6倍.，明顯增加，而血清中尿酸濃 度與正常鼠相比約上升2〇_25%。餵食人蔘花萃取物的組別 心果顯不’與疾病模型組相比，可觀察到尿酸排除率平均 问於3000 pg/3h ’高於疾病模型組；血清中尿酸含量平均 201247212 為13.5及11·3 gg/ml，低於疾病模型組；整體尿酸清除約 為每分鐘7.1及8.9 ml.，顯著高於疾病模型組的3·6 ml。而 且可觀察到人蔘花萃取物水溶液濃度增加後，大鼠整體尿 酸清除也隨之增加。 表一：人蔘粉末對誘導產生高尿酸大鼠之影響 組別 尿液量 (mL) 尿酸濃度 (pg/ml) 尿酸排除率 _hr) 血清中尿酸 濃度(pg/ml) 尿酸清除* mL/min 正常鼠 5 士 1.1 80.18 土 18.6 398.46±118.5 10.88±1.4 1.07 土 0.5 疾病模型 7.2 士 1.7 297.6±106.1 2219.54±1001.5 13.42±2 6.7±3.4 0X0+人蔘 粉未250 mg/kg 7.8±3.1 390.8土 71.4 3071.95土1302.5 13.9±2.1 10·03±6·6 0X0+人蔘 粉末500 mg/kg 7.1±1.9 399.8±61.9 2877.9±944.5 15.12±2.8 8.65±6 *尿酸清除=3小時尿液中尿酸排除率/血清中尿酸含量*老鼠3小時 收集尿液體積/180=整體尿酸清除每分鐘之體積 201247212 表二：人蔘花萃取物對誘導產生高尿酸大鼠之影響 組別 尿液量 尿酸濃度 尿酸排除率 血清中尿酸 尿酸清除* (mL) (pg/ml) (pg/3hr) 濃度(pg/ml) mL/min 正常鼠 3.6±2.1 114.8 士 65 354.3±222.4 10.3 土 2:6 0.8±0.5 疾病模型 3.2±1.9 783.8±255.5 2585.8±1211.4 13.7±2.9 3.6士4.7 0X0+人蔘花 5.5±0.8 612.1±304.6 3198.1±1108.4 13.5±3 7,1±1.9 100 mg/kg 0X0+人蔘花 5.6 土 1.8 620.3±210.1 3128.0 士527.4 11.3 土 1.9 8.9±2.5 250 mg/kg 牛同表一 由實驗結果分析可得以下幾點結論：1. 口服人蔘粉或 人蔘花萃取物皆提高尿液尿酸排除量，比疾病模型組名多 出約30〜4〇%(人蔘粉）和24%(人蔘花萃取物）；2. 口服人蔘 花萃取物對降低叙中尿酸含量或促進體内尿酸的清除皆有 改善作用’尤其是對體内尿酸的清除能力較疾病模型組增 強約.2〜2.5倍。但是’ 口服人蔘粉對降低血中尿酸含量或 促進體内尿酸的清除作用不大。尤其人蔘花萃取物250 mg/kg劑量的效量還遠優於人蔘粉末劑量5〇〇 mg/kg者。整 體試驗結果指出人蔘花萃取物具有預防及改善痛風症狀的 效果°目前治療痛風及高尿酸血症之藥物，皆具有其他副 作用。人蔘花除了先前已知抗疲勞之作用之功效，本發明 實驗亦證明人赛花萃取物還可預防尿酸過高，具有改善痛 風症狀。 11 201247212 雖然本發明已利用上述實施例說明，但是本發明並不 被所揭露的實施例所限制，熟悉本項技藝之人士仍可作出 不脫離本發明範圍之修飾及變化。 12201247212 Increasing Trends According to a study by the National Institutes of Health, the prevalence of gout in the male population over 30 years old is as high as 3.3%. This has a very high relationship with the rapid growth of the economy and the changes in people's eating habits, that is, the increase in the consumption of animal protein, fat and wine. The fat and fat population is getting more and more younger, so the population with too high uric acid is rising rapidly, and the age of gout attacks is getting younger and younger. According to the statistics of the causes of death in gout patients in Europe and the United States, the most common complications due to gout are the combination of ischemic heart disease and uremia and cerebrovascular disease. In Japan, research in Asia is the first in uremia, followed by ischemic heart disease and cerebrovascular disease. Regardless of the complications, it is a must for gout patients. Current treatments for gout In general, during acute gout, the most important thing is to reduce the onset of pain rather than lowering the concentration of uric acid. First, give the injured joints a full rest, usually take the treatment of colchicine, but because colchicine has a slow time, so when colchicine can not inhibit inflammation and persistent pain, it is necessary to use non-steroidal anti-inflammatory analgesics . However, in the elderly and patients with poor liver and kidney function, if you want to use colchicine, you should be very careful about the use of colchicine in the acute phase of treatment. When the joint pain is improved, it often causes abdominal and gastrointestinal symptoms. In addition, in the case of uric acid-lowering drugs, it is mainly used to promote the uric acid excretion drug (Benzbr〇marone) and the uric acid-producing drug (Allopurinol) to determine the type of drug to be used depending on the condition and comorbidity of the patient. However, the side effects of both drugs can damage the liver and cause an increase in the GOP and GDP index, so liver function must be checked regularly during treatment. 201247212 Radix Gingseng is the dry root of c. A. Meyer of the genus Aconitum, and many studies have shown that there are many chemical compounds such as saponins, human scorpion polysaccharides and protein amino acids in human mites. Knives, in which saponins are the main essential components. Currently, more than 80 kinds of human saponins are known to be isolated from human mites. Studies have shown that human 蔘4 R R, Rd, Rgl, Rg3, Rhl And Rh2 has the functions of tumor cell proliferation and invasion, metastasis, inhibition of vascular endothelial cell proliferation, promotion of cancer apoptosis, regulation of immune function, adjustment of blood sugar, delay of aging and anti-fatigue. In recent years, research on human sputum has also shown that it contains a large amount of trace elements and alkaloids of saponin active substances, and the content of bud saponins is more than 5 times higher than that of human radix. It has the functions of nourishing qi and activating blood circulation, regulating endocrine, promoting metabolism, etc. It can also use various health effects such as clearing heat and reducing inflammation, and calming the liver to lower blood pressure. Therefore, it is widely used as edible tea for health care. Studies have also shown that human 蔘 flower extract has anti-fatigue effects in mice. SUMMARY OF THE INVENTION A primary object of the present invention is to provide an active ingredient for preventing or treating diseases or symptoms caused by excessive uric acid in the blood. Another object of the present invention is to provide a pharmaceutical or pharmaceutical composition for preventing or treating a disease or symptom caused by excessive uric acid in the blood. A further object of the present invention is to provide a herbal extract which prevents or treats diseases or symptoms caused by excessive uric acid in the blood. In order to achieve the above object, the present invention provides a use of the human Zhaihua extract as an active ingredient for preparing a medicament for preventing or treating a disease or symptom caused by high uric acid in the blood of 201247212. The extract of the scented flower is the extract of the ritual of Panax ginseng c A Meyer. Preferably, the human flower extract is preferably an aqueous extract, an organic solvent extract, or a carbon dioxide supercritical fluid extract, the organic solvent extract being a C1-C4 alcohol, acetone, ethyl acetate or diethyl ether. Extracts. Preferably, the human silk flower extract is a polar solvent extract. More preferably, the polar solvent extract is an extract of water, an alcohol, or a mixed solvent thereof. Most preferably, the polar solvent extract is an extract of a mixed solvent of water and a C1C4 alcohol, for example, an alcohol sterol or ethanol. In a preferred embodiment of the invention, the C1_C4 alcohol extract is decyl alcohol. Preferably, the human silk flower extract is prepared by a method comprising the steps of: mixing a mixed solvent of human iris flower powder with water and methanol under shaking; separating the mixture of the powder and the solvent by solid-liquid separation to obtain a supernatant. And extracting the supernatant to obtain the human silk flower extract. Preferably, the drug is in an oral dosage form. Preferably, the disease or symptom caused by excessive uric acid in the blood is gout, hyperuricemia, kidney stones or gouty nephropathy. Preferably, the disease or symptom caused by excessive uric acid in the blood is gout. Preferably, the disease or symptom caused by excessive uric acid in the blood is hyperuricemia β. Mammals are human. In the following description, the present invention proves that the first 6 201247212 ingestion of human scented flower extract has the function of increasing the amount of uric acid excreted by urine and lowering the concentration of uric acid in the blood, and its efficacy is superior to that of expensive people.蔘 extract. [Embodiment] The present invention will experimentally investigate whether human extracts and human silk flower extracts can promote the elimination of excessive uric acid in hyperuric rats. After the human sputum powder aqueous solution and the human scutellaria extract were orally administered to the rats, the rats were induced to form a high uric acid by 〇x〇nate (drug name), and whether the human sputum powder aqueous solution and the human scented flower extract were observed. It has the effect of promoting the elimination of excess uric acid in rats after induction of high uric acid. The invention is further described in detail below with reference to the embodiments, but without restricting the invention. Example 1 Finely mixed human 蔘gzwewg CA Meyer) Flower powder sample 10 g 'mixed with 100 mL of 50% aqueous methanol solution, placed on an ultrasonic oscillator for 1 hour, and then at 1 3000 rpm Although the rotation speed is 10 minutes, take about 99 mL of the supernatant and put it in the sample bottle. Dry under reduced pressure and obtain a total weight of 4-18 g, and the extraction rate is about 41.8%. Drug: Oxonate, sodium salt of cellulose carboxymethyl ether (Carboxy me thy 1 Cellulose Sodium (CMC) and uric acid standards were purchased from Sigma; human powder gambling from Bingham Pharmaceutical; human silk flower extract was prepared for this example ❶ Animals: 6-8 weeks old SD male mouse purchased from Lesco Biotechnology company. 2 201247212 Rat-raised cages provide rat feed, litter and adequate supply of clean drinking water. The breeding environment is 12 hours of light, room temperature i 8_28〇c, relative fishery 40-70% environment. Experimental method: Preparation before the experiment: The rats were fasted the day before (6 pm to 9:00 the next morning). After drug configuration, metabolic cage placement and body weight measurement, they were grouped by sampling, 4-6 per group. Music configuration. 0.8% CMC is evenly dissolved in sterile water to 〇 80/. The CMC aqueous solution was formulated with a 40 mg/ml 〇xonate suspension and the dose of 〇x〇nate was 200 mg/kg (5 ml/kg). The human enamel powder was formulated with a uniform suspension of 25 and 50 mg/kg concentrations in sterile water. The human scented flower extract was placed in sterile water with a uniform suspension of 1 〇 and 25 mg/kg. The dosage of human enamel powder is 25 〇 and 500 mg/kg (10 ml/kg); the dosage of human 蔘 flower extract is 1〇〇, 250 mg/kg (10 ml/kg) ° Experiment and sampling: Rat oral After 3 minutes, the human sputum powder or human scented flower extract was injected with IP to induce the drug Oxonate, and the rats were placed in the metabolic dragon for 3 hours' after collecting their urine and recording volume. The blood was allowed to stand for 30 minutes. The speed of 3000 rpm is 4. Centrifuge for 15-20 minutes and collect the upper serum. Urine and serum were separately stored and stored in a _2 degree refrigerator for use. Sample analysis · HPLC analysis of serum and urine uric acid content, equipment and methods are as follows: B403 HPLC system (TSP P1000 pump, SN4000 controller, UV6000 UV detector), using the column for HC C18 Aglient 4.6x250 mm; standard with 0.02 % NaN3 was prepared at 100 201247212 mg/mL and diluted to 0.5, 5, 6, 7, 8, 10, 20, 30 pg/mL. The sample was diluted to a suitable concentration with 0.02% NaN3 and analyzed. Tables 1 and 2 respectively show the effects of human enamel powder and human scutellaria extract on the induction of high uric acid in rats, including normal rat sputum (not induced by drug Oxonate) and disease model group (induced by drug 〇oxate). And did not pre-administer the drug). As shown in Table 1, the average uric acid excretion rate detected in the urine of the normal rat group was 398.5 pg/3 hr after 3 hours, and the average uric acid content in the serum was 1 0.8 8 pg/m. In the disease model group, the uric acid elimination rate was about 5-6 times higher than that of normal mice, and the overall uric acid clearance was 6 times higher than that per minute, which was significantly increased, while the serum uric acid concentration was normal with sputum. It is about 20% higher than about. After feeding the human glutinous powder, the levee showed that the urine uric acid elimination rate and the overall uric acid clearance were slightly increased compared with the disease model group, while the serum uric acid content did not decrease compared with the disease model group. The dose of the human yolk powder did not reduce the effect of uric acid in the serum. As shown in Table 2, the average uric acid excretion rate detected in the urine of the normal rat group was 354 3 gg/3h after 3 hours, and the average uric acid content in the serum was 10.3 pg/ml. 〇 8 ml; while the disease model group had a higher uric acid elimination rate than normal mice - about 6-7 times, the overall uric acid clearance was about 5.6 times higher per minute. It increased significantly, while the serum uric acid concentration was normal. The rat increased by about 2〇_25%. The concentration of uric acid excretion rate was higher than that of the disease model group compared with the disease model group. The average uric acid content in the serum was 2012.51212 and 13.5 and 11·3 gg/ml, lower than the disease model group; the overall uric acid clearance was about 7.1 and 8.9 ml per minute, which was significantly higher than the 3. 6 ml of the disease model group. Moreover, it can be observed that after the concentration of the aqueous solution of the human scented flower extract is increased, the overall uric acid clearance of the rat is also increased. Table 1: Effect of human bismuth powder on rats induced to produce high uric acid Urine volume (mL) Uric acid concentration (pg/ml) Uric acid exclusion rate _hr) Serum uric acid concentration (pg/ml) Uric acid clearance * mL/ Min normal rats 5 ± 1.1 80.18 soil 18.6 398.46 ± 118.5 10.88 ± 1.4 1.07 soil 0.5 disease model 7.2 ± 1.7 297.6 ± 106.1 2219.54 ± 1001.5 13.42 ± 2 6.7 ± 3.4 0X0 + human powder no 250 mg / kg 7.8 ± 3.1 390.8 soil 71.4 3071.95 soil 1302.5 13.9±2.1 10·03±6·6 0X0+ human 蔘 powder 500 mg/kg 7.1±1.9 399.8±61.9 2877.9±944.5 15.12±2.8 8.65±6 * uric acid clearance = 3 hours urine uric acid elimination rate / serum Middle uric acid content * Rats collected urine volume for 3 hours / 180 = overall uric acid clearance volume per minute 201247212 Table 2: Effect of human scutellaria extract on induced high uric acid in rats Group urine uric acid concentration uric acid exclusion rate serum Uric acid uric acid clearance* (mL) (pg/ml) (pg/3hr) Concentration (pg/ml) mL/min Normal rats 3.6 ± 2.1 114.8 ± 65 354.3 ± 222.4 10.3 Soil 2: 6 0.8 ± 0.5 Disease model 3.2 ± 1.9 783.8±255.5 2585.8±1211.4 13.7±2.9 3.6 4.7 4.7 0X0+ human 蔘花 5.5±0.8 612.1±304.6 3198.1±1108.4 13.5±3 7,1±1.9 100 mg/kg 0X0+Human 5.6花5.6 Soil 1.8 620.3±210.1 3128.0 Shi 527.4 11.3 Soil 1.9 8.9±2.5 250 mg/kg Niu Tongyi Table 1 Some conclusions: 1. Oral human sputum powder or human scented flower extract can increase urine uric acid excretion, about 30~4%% (human powder) and 24% (human scented flower extract) than the disease model group name. 2. Oral human scented flower extract can improve the uric acid content in the sputum or promote the removal of uric acid in the body', especially the uric acid scavenging ability of the body is about 2.~2.5 times stronger than the disease model group. However, oral human sputum powder has little effect on reducing blood uric acid content or promoting uric acid clearance in the body. In particular, the dose of 250 mg/kg of Astragalus membranaceus extract is far superior to that of human 蔘 powder dose of 5 〇〇 mg/kg. The results of the whole experiment indicated that the extract of Astragalus membranaceus has the effect of preventing and improving the symptoms of gout. Currently, the drugs for treating gout and hyperuricemia have other side effects. In addition to the previously known effects of anti-fatigue effects, the experiment of the present invention also proves that the human flower extract can also prevent uric acid from being too high and has an improvement in gout symptoms. The present invention has been described with reference to the above-described embodiments, but the invention is not limited by the disclosed embodiments, and those skilled in the art can make modifications and variations without departing from the scope of the invention. 12